NEGATIVE REGULATION OF AUTOREACTIVE T-CELLS
自身反应性 T 细胞的负调控
基本信息
- 批准号:6892223
- 负责人:
- 金额:$ 2.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-01 至 2005-07-31
- 项目状态:已结题
- 来源:
- 关键词:MHC class II antigen T cell receptor age difference autoantigens autoimmune disorder biological signal transduction gene expression genetically modified animals helper T lymphocyte immune tolerance /unresponsiveness immunoglobulin structure immunologic memory immunoregulation insulin dependent diabetes mellitus laboratory mouse longitudinal animal study recombinant proteins tissue mosaicism
项目摘要
DESCRIPTION (provided by applicant): This is a proposal to explore the
mechanisms of long-term tolerance of autoreactive CD4 T-cells induced by
soluble MHC II/Fc/peptide chimeras. Our preliminary results indicated that
short therapy with MHC II/Fc/peptide chimeras of prediabetic mice induced
regulatory mechanisms responsible for tolerance to a self autoantigen, and
offered protection against the disease onset for as long as 8 months. Using a
double transgenic mouse model for insulin-dependent diabetes mellitus (IDDM)
in which the autoreactive T-cells specific for a defined self epitope were not
deleted by thymic selection, and they were not tolerized in periphery, we
propose to explore the cellular, and molecular mechanisms induced by MHC
II/Fc/peptide chimera leading to antigen-specific long-term tolerance.
Manipulation of the antigen-specific tolerance to immunodominant autoreactive
epitopes in the neonatal life, may soon lead to novel strategies aimed at
arresting the epitope spreading in autoimmune diseases. Deciphering the
cellular and molecular basis of these mechanisms may also offer a better
understanding of why antigen-specific long-term tolerance can be easily
induced in the neonatal life, but not in the adult life. In the first part of
this application we will (1) investigate the ability of MHC II/Fc/peptide
chimera to induce protective Th2 memory responses and regulatory/suppressor
cells during particular age-windows, (2) characterize immunophenotypically and
functionally the fate of these cells in adulthood, and (3) define their
protective capacity against autoimmune diabetes in the IDDM double transgenic
mouse model. In the second part, we will (1) explore the biochemical nature of
several transductional and transcriptional events that can be differentially
induced by MHC II/Fc/peptide chimera in early life, and that may affect the
fate of Th2 and regulatory/suppressor cells in adulthood, and (2) investigate
the biochemical nature of tolerogenic signals induced by regulatory/suppressor
cells in the autoreactive T-cells in the target organ. Satisfactory results of
this study will expand our area of investigations on the human MHC
II/Fc/peptide-like reagents carrying immunodominant autoreactive epitopes
relevant for human autoimmune diseases. The antigen-specific tolerogenicity of
these reagents will be evaluated in in vitro systems, and in double transgenic
mice deficient for the murine MHC class II, and expressing human HLA-DR*
alleles.
描述(由申请人提供): 这是一个探讨
诱导自身反应性CD 4 T细胞长期耐受的机制
可溶性MHC II/Fc/肽嵌合体。我们的初步结果表明,
用MHC II/Fc/肽嵌合体诱导的糖尿病前期小鼠的短期治疗
负责对自身自身抗原耐受的调节机制,和
提供了长达8个月的预防疾病发作的保护。使用
胰岛素依赖型糖尿病双转基因小鼠模型
其中对确定的自身表位特异性的自身反应性T细胞不
删除胸腺选择,他们没有耐受的外围,我们
建议探索MHC诱导的细胞和分子机制
II/Fc/肽 嵌合体导致 抗原特异性长期耐受性。
对免疫显性自身反应的抗原特异性耐受的操纵
表位在新生儿的生活,可能很快导致新的战略,旨在
阻止自身免疫性疾病中的表位扩散。 破译
这些机制的细胞和分子基础也可能提供更好的
了解为什么抗原特异性长期耐受可以很容易地
在新生儿期诱导,但在成年期不诱导。第一部分
本申请我们将(1)研究MHC II/Fc/肽的能力,
嵌合体诱导保护性Th 2记忆应答和调节/抑制
在特定年龄窗期间的细胞,(2)表征免疫表型,
这些细胞在成年期的命运,以及(3)定义它们的功能。
胰岛素依赖型糖尿病双转基因小鼠对自身免疫性糖尿病的保护能力
小鼠模型在第二部分中,我们将(1)探索生物化学的本质,
几个转导和转录事件,可以差异
诱导的MHC II/Fc/肽嵌合体在生命早期,这可能会影响
Th 2和调节/抑制细胞在成年期的命运,以及(2)研究
调节/抑制因子诱导的致耐受性信号的生物化学性质
靶器官中的自身反应性T细胞。合格的食物样本
这项研究将扩大我们的领域 对人类MHC的研究
携带免疫显性自身反应性表位的II/Fc/肽样试剂
与人类自身免疫性疾病有关。的抗原特异性耐受原性
这些试剂将在体外系统中进行评价,
小鼠MHCII类缺陷,并表达人HLA-DR*
等位基因。
项目成果
期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
RNA degradation precedes DNA cleavage in autoreactive CD4 T cells suppressed by calicheamicin gamma1.
- DOI:10.1016/j.intimp.2004.01.002
- 发表时间:2004-04
- 期刊:
- 影响因子:5.6
- 作者:Sunil Thomas;Anca Preda-Pais;S. Casares;T. Brumeanu
- 通讯作者:Sunil Thomas;Anca Preda-Pais;S. Casares;T. Brumeanu
Double negative (CD3+ 4- 8-) TCR alphabeta splenic cells from young NOD mice provide long-lasting protection against type 1 diabetes.
- DOI:10.1371/journal.pone.0011427
- 发表时间:2010-07-02
- 期刊:
- 影响因子:3.7
- 作者:Duncan B;Nazarov-Stoica C;Surls J;Kehl M;Bona C;Casares S;Brumeanu TD
- 通讯作者:Brumeanu TD
Role of lipid rafts in T cells.
脂筏在 T 细胞中的作用。
- DOI:
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Thomas,Sunil;Kumar,RajeevS;Brumeanu,Teodor-D
- 通讯作者:Brumeanu,Teodor-D
Efficacy of clonal deletion vs. anergy of self-reactive CD4 T-cells for the prevention and reversal of autoimmune diabetes.
克隆缺失与自身反应性 CD4 T 细胞无反应对于预防和逆转自身免疫性糖尿病的功效。
- DOI:10.1016/j.jaut.2005.04.003
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Preda-Pais,Anca;Stan,AlexandruC;Casares,Sofia;Bona,Constantin;Brumeanu,Teodor-D
- 通讯作者:Brumeanu,Teodor-D
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TEODOR-DORU BRUMEANU BRUMEANU其他文献
TEODOR-DORU BRUMEANU BRUMEANU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TEODOR-DORU BRUMEANU BRUMEANU', 18)}}的其他基金
Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
- 批准号:
6524692 - 财政年份:2001
- 资助金额:
$ 2.59万 - 项目类别:
Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
- 批准号:
6931625 - 财政年份:2001
- 资助金额:
$ 2.59万 - 项目类别:
Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
- 批准号:
6789342 - 财政年份:2001
- 资助金额:
$ 2.59万 - 项目类别:
Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
- 批准号:
6892222 - 财政年份:2001
- 资助金额:
$ 2.59万 - 项目类别:
Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
- 批准号:
6500182 - 财政年份:2001
- 资助金额:
$ 2.59万 - 项目类别:
Prevention Type 1 diabetes by soluble, MHC II-peptide
通过可溶性 MHC II 肽预防 1 型糖尿病
- 批准号:
6647111 - 财政年份:2001
- 资助金额:
$ 2.59万 - 项目类别:
相似海外基金
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23K28188 - 财政年份:2024
- 资助金额:
$ 2.59万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
The molecular basis of T cell receptor cross-reactivity between MHC and MR1
MHC 和 MR1 之间 T 细胞受体交叉反应的分子基础
- 批准号:
DP240102905 - 财政年份:2024
- 资助金额:
$ 2.59万 - 项目类别:
Discovery Projects
CAREER: Understanding the Impact of Dephosphorylation Kinetics and Adapter Specificity on Synthetic T Cell Receptor Signaling and Function
职业:了解去磷酸化动力学和接头特异性对合成 T 细胞受体信号传导和功能的影响
- 批准号:
2339172 - 财政年份:2024
- 资助金额:
$ 2.59万 - 项目类别:
Continuing Grant
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
预测癌症患者预后的特殊公共 T 细胞受体序列
- 批准号:
10577518 - 财政年份:2023
- 资助金额:
$ 2.59万 - 项目类别:
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23H03498 - 财政年份:2023
- 资助金额:
$ 2.59万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Impact of T cell receptor signaling on memory CD8+ T cell stemness
T 细胞受体信号传导对记忆 CD8 T 细胞干性的影响
- 批准号:
10676407 - 财政年份:2023
- 资助金额:
$ 2.59万 - 项目类别:
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
- 批准号:
22KK0277 - 财政年份:2023
- 资助金额:
$ 2.59万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy
使用体内新型免疫原策略生成 T 细胞受体模拟亲和试剂
- 批准号:
10599584 - 财政年份:2023
- 资助金额:
$ 2.59万 - 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
- 批准号:
10530023 - 财政年份:2022
- 资助金额:
$ 2.59万 - 项目类别:
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
- 批准号:
10684172 - 财政年份:2022
- 资助金额:
$ 2.59万 - 项目类别: